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With over 38000 new cases each year, lung cancer is the second
most common form of cancer in the United Kingdom after breast
cancer (Cancer Research UK, 2008a) and it is the most common
cancer cause of death (Cancer Research UK, 2008b). Tobacco
smoking is undoubtedly the major aetiological risk factor, the risk
being around ten times higher in long-term smokers compared
with non-smokers (Doll and Peto, 1981). Men are more likely to be
affected, although the number of women with lung cancer has been
increasing. This reflects changes in smoking habits over the last
century (Quinn et al, 2001). Smoking cessation before middle age
avoids more than 90% of the lung cancer risk attributable to
tobacco (Peto et al, 2000).
Lung cancer can be broadly classified into two main types: non-
small-cell lung cancer (NSCLC), which accounts for about 80% of
cases, and small-cell lung cancer (SCLC), which accounts for the
other 20%. Approximately 70% of patients with NSCLC present
with advanced (Stage III/IV) disease (Ihde and Minna, 1991; Ihde,
1992). At diagnosis, about 60% of patients with SCLC have
extensive disease, defined as disease not contained within a
hemithorax, with metastases involving one or more sites such as
the brain, liver, bone or bone marrow (Carney, 2002).
STANDARDS OF DIAGNOSIS BETWEEN 1985
AND 2000
No screening services are provided for early detection of cancer of
the lung in England and Wales as there is currently no evidence
that population screening is effective in reducing mortality
(Manser et al, 2003). Most patients in the United Kingdom present
to their primary care physician. Lung cancer should be suspected
in any smoker with new or worsening respiratory symptoms
including haemoptysis, or indication of systemic illness such as
anorexia, malaise or weight loss (NICE, 2005). If a chest X-ray
suggests lung cancer, then patients are offered urgent referral to a
member of the lung cancer multidisciplinary team, usually a chest
physician. The diagnosis may be confirmed from sputum cytology,
bronchoscopy, percutaneous needle biopsy or open biopsy.
Staging of lung cancers is by computed tomography (CT). Prompt
referral and good teamwork are essential at every stage of
management. Many advances in diagnosis and treatment have
the potential to improve outcome in lung cancer. These demand
a high degree of specialisation and multidisciplinary care.
Such recommendations have appeared in guidelines published
in the 1990s (SMAC, 1994; BTS, 1998; NHSE, 1998; SIGN, 1998).
Positron emission tomography (PET) imaging became clinically
available in a limited number of centres in the mid-1990s. It is
a useful tool for refining the diagnosis and staging in patients
with possible lung cancer. More recent guidelines recommend
that patients who are staged as candidates for surgery or
radical radiotherapy on CT should have an
18F-deoxyglucose-
PET (FDG-PET) scan to look for involved intrathoracic lymph
nodes and distant metastases (NICE, 2005). However, solitary
extrapulmonary focal FDG accumulation may be due to a benign
tumour or to inflammation. (Lardinois et al, 2005).
TREATMENT OF LUNG CANCER BETWEEN 1985
AND 2000
Management of a patient with lung cancer depends largely on
tumour type, extent of disease, general performance status of the
patient and any significant comorbidity.
Surgery is the treatment of choice for operable patients with
resectable Stage I and II NSCLC (Reif et al, 2000). Surgery also has
an important role in managing selected patients with resectable
Stage IIIA disease, sometimes in the context of combined modality
therapy (Mountain, 1988; Reif et al, 2000). However, fewer than
20% of NSCLC patients have disease that is resectable at
presentation (Martini and Flehinger, 1987). In spite of the
intention to consider all patients with Stage I and II disease for
surgery, there are those who, although technically operable, either
decline surgery or are considered inoperable because of poor
respiratory reserve, cardiovascular disease or general frailty. These
‘medically inoperable’ patients may be offered radical radiotherapy
(RCR, 1999). Continuous hyperfractionated accelerated radio-
therapy (CHART) compared with conventional radiotherapy gives
a significant improvement in survival for patients with NSCLC
(Saunders et al, 1997), although in 1998, CHART was not available
in most UK centres.
However, in the majority of patients with NSCLC, advanced
disease within the chest or metastatic disease precludes potentially
curative treatment. For these patients, the aim of treatment is
primarily palliative. In the 1980s and for most of the 1990s, there
was substantial disagreement, both nationally and internationally,
about the role of chemotherapy in addition to palliative radio-
therapy and active supportive care (Carroll et al, 1986; Aisner and
Belani, 1993; SMAC, 1994).
A meta-analysis of chemotherapy in NSCLC demonstrated a
survival benefit in favour of cisplatin-based chemotherapy that
reached conventional levels of significance when used with radical
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most common treatment for NSCLC in the United Kingdom in the
1990s was cisplatin-based, usually mitomycin C, vinblastine and
cisplatin (MVP) (Waters and O’Brien, 2002).
The mainstay of treatment in SCLC is combination chemo-
therapy. Commonly used combination chemotherapy regimes in
the 1980s and 1990s include cyclophosphamide, doxorubicin and
vincristine (CAV), cisplatin and etoposide (PE) and carboplatin
and etoposide (CE). In limited SCLC, chemotherapy combined
with thoracic radiotherapy yields 50–85% complete response
rates, a median survival duration of 12–20 months and
two year disease-free survival rates of 15–40% (Albain et al,
1990; Arriagada et al, 1992; Turrisi et al, 1999). Local treatments
such as resection and radiotherapy have a limited effect in
extensive SCLC (Souhami and Law, 1990) so the most widely
accepted option for treating extensive disease is also with
combination platinum-based chemotherapy. Despite diverse
strategies for the treatment of patients with extensive SCLC,
the results of phase III trials over the past 25 years have shown
only a 2-month prolongation in median survival time between
patients treated with different regimens (Chute et al, 1999). A more
recent advance has been that prophylactic cranial irradiation
significantly improves survival and disease-free survival for
patients with SCLC in complete remission following chemotherapy
(Auperin et al, 1999).
LUNG CANCER SURVIVAL TRENDS IN ENGLAND
AND WALES
The key trends in lung cancer survival as reported by
Coleman et al (2004) are that 5-year survival for lung
cancer increased marginally (on average 0.1% every 5 years)
for men and women diagnosed in England and Wales over
1986–1999 but the average increase every 5 years during the
1990s was not statistically significant. Five-year survival for lung
cancer patients diagnosed during 1996–1999 was 6% in men and
women, not significantly better than for patients diagnosed a
decade or so earlier. However, 1-year survival rates have risen
from 15 to 25% for men and 13 to 26% for women diagnosed
between 1971–1975 (Coleman et al, 1999) and 2000–2001
(Coleman et al, 2004).
There is good evidence that active treatment with surgery,
radiotherapy or chemotherapy may improve survival in lung
cancer and should not be denied to patients who might benefit
(Brown et al, 1996; Fergusson et al, 1996; Muers and Haward,
1996). Higher rates and improving survival (5-year relative
survival up to 14%) reported by some European countries must
raise the possibility that opportunities exist for improvement. The
EUROCARE-4 study identified considerable geographic variation
of 12.3% in the 5-year survival rate for lung cancer across Europe,
with the highest rates found in the Nordic region and central
Europe, intermediate rates in southern Europe, lower rates in the
United Kingdom and Ireland and the lowest rates in eastern
Europe (Berrino et al, 2007).
Survival of NSCLC is largely dependent upon successful
surgery. However, patients presenting with symptoms suggestive of
lung cancer often experience delay at every stage of the referral
process. The mean total delay experienced by patients from
presentation to surgery was 109 days, including 1 month before
initial referral to a specialist, and 2 months before subsequent
referral to a surgeon (Billing and Wells, 1996). The annual national
summary of resections for lung cancer carried out by all
UK cardiothoracic surgeons shows a stable but lower figure of
10% (SCSGBI, 1994) compared with other European countries
and the United States. There is therefore concern that many
patients with operable tumours may be denied the chance of curative
surgery.
There is an association between higher proportions of patients
with a histological diagnosis and improved survival rates.
An optimal proportion of patients with a histological diagnosis
is generally considered to be around 80%. However, not all
cases are confirmed histologically. Up until 1990, the rate was
50–60% (Connolly et al, 1990; Watkin et al, 1990), but by 1992–
1994 this had improved to 70% in the Northern and Yorkshire
region (NYCRIS, 1999). The rate of histological diagnosis
decreases with age to 55% in patients aged 75–84 years
(Kesson et al, 1998).
Despite evidence that chemotherapy may improve survival in
some groups of lung cancer patients, only a small proportion of
patients in the United Kingdom with NSCLC have been receiving
chemotherapy (Clegg et al, 2001). For example, only 12% of people
diagnosed with lung cancer in Wales in 1996 were given
chemotherapy (WTS, 2000). There remained a widespread belief
that chemotherapy for lung cancer was toxic and ineffective and a
survey of clinicians who treated lung cancer in the United Kingdom
found little support for chemotherapy (Crook et al, 1997).
Geographical differences exist in lung cancer survival.
A study of over 24500 cases of lung cancer between 1986 and
1994 found notable differences in 1- and 2-year survival between
districts of residence in the Northern and Yorkshire region
(NYCRIS, 1999). For example, 2-year survival in NSCLC varied
by district between 7 and 18%. Five-year survival rates vary
between different English health authorities, ranging from 2.2 to
8.9%, for patients diagnosed with lung cancer between 1993 and
1995 (DOH, 2002). There were wide variations in the rates of active
treatment between districts and active treatment was strongly
associated with improved survival (Cartman et al, 2002). A
separate study of lung cancer patients diagnosed in southeast
England between 1995 and 1999 found evidence for geographical
inequality in the treatment given and patient survival (Jack et al,
2003). This study also found that patients whose first hospital
attendance was at a radiotherapy centre survived longer and
that the geographical inequalities may be explained by variations
in access to oncology services.
This clinical background against which the study by Coleman
et al was performed would suggest scope for improvement in the
management of lung cancer.
SOCIOECONOMIC INEQUALITIES IN LUNG CANCER
SURVIVAL IN ENGLAND AND WALES
Coleman et al (2004) found that survival among men was
significantly lower for the poor than for the rich (deprivation
gap 1.4%), a wider gap than for men diagnosed during 1986–
1990, although the 5-yearly increase in the gap was not itself
significant. The deprivation gap in survival for women diagnosed
during 1996–1999 was small, and unchanged from a decade
earlier.
The socioeconomic inequality in lung cancer survival among
men may reflect a higher proportion of patients from the more
deprived socioeconomic groups being more likely to present with
comorbidity related to smoking, such as chronic obstructive
pulmonary disease and ischaemic heart disease. In the case of
NSCLC, patients from the most deprived groups may present with
more advanced disease. Such factors may influence treatment,
particularly surgery rates. Residents of a more deprived area may
also be less likely to receive any active treatment, chemotherapy or
radiotherapy (NYCRIS, 1999; Jack et al, 2003). Lower socio-
economic groups tend to use NHS services less in relation to
need – this may reflect longer travel time, greater travel cost, lower
car ownership, time constraints, differences in knowledge or
beliefs about the need for medical attention (Dixon et al, 2003).
However, these factors would also be expected to influence the
deprivation gap in survival for women.
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TREATMENT
There have been many significant developments in the
treatment of lung cancer since the turn of the century. The
proportion of patients with NSCLC receiving active treatment
has increased. There is strong evidence to recommend adjuvant
chemotherapy for patients after resection of early NSCLC
(Visbal et al, 2005). A further survival benefit has been identified
in the treatment of Stage III NSCLC with chemoradiotherapy
compared with radiotherapy alone (Rowell and O’Rourke, 2004).
First-line treatment of advanced NSCLC with third-generation
regimens incorporating gemcitabine, paclitaxel, vinorelbine
or docetaxel with a platinum-based drug, have replaced
second-generation agents like mitomycin C and vinblastine.
Addition of anti-angiogenic agents to chemotherapy has been
shown to be beneficial for patients with non-squamous NSCLC,
although this is unlikely to be considered cost-effective within the
NHS (Sandler et al, 2006). There is now a role for second-line
treatment with docetaxel monotherapy (NICE, 2005). Epidermal
growth factor receptor (EGFR) inhibition with erlotinib
may prolong survival in patients with NSCLC after first-line or
second-line chemotherapy (Shepherd et al, 2005). At the
time of writing erlotinib is not generally available for NHS
patients pending an imminent final decision by NICE.
The Scottish Medicines Consortium accepted the case for
erlotinib in the second-line treatment of NSCLC in May 2006
(SMC, 2006).
CONCLUSION
Although cancer survival improved for most cancers in both sexes
during the 1990s, the figures for lung cancer make for bleak
reading. The need to standardise cancer care and treatment has
been recognised by the Department of Health (DOH, 1995). This
was followed by guidelines published in the 1990s aimed at
improving outcomes in lung cancer (SMAC, 1994; BTS, 1998;
NHSE, 1998; SIGN, 1998). However, it is unlikely that these
initiatives will have significantly influenced the management of
lung cancer between 1996 and 1999. There is usually a substantial
time lag from publication of guidance to its implementation and
any subsequent improvement in outcomes.
There have since been further initiatives like the NHS Cancer
Plan (DOH, 2000). This was the first ever comprehensive strategy
linking cancer prevention, diagnosis, treatment, care and research.
The strategy was updated in 2004 in the NHS Cancer Plan and The
New NHS. There have been many positive developments such as
the emergence of the lung cancer specialist nurse service, the
creation of lung cancer multidisciplinary teams, and the improve-
ment in the evidence base for treatment, especially the third-
generation chemotherapy agents. Developments in technology,
such as FDG-PET scanning in disease staging, and the greater
availability of CHART for the delivery of radical radiotherapy in
suitable patients should be highlighted. These elements have been
incorporated into detailed national guidelines for the diagnosis
and treatment of lung cancer (NICE, 2005).
The study by Coleman et al provides baseline data to evaluate the
efficacy of the restructuring of cancer services in England and Wales.
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